CGNNT(SZ:000881)2022-04-29 16:00Financial Performance - The company's operating revenue for 2021 was ¥7,998,857,682.91, representing a 20.25% increase from ¥6,651,679,590.05 in 2020[32]. - The net profit attributable to shareholders for 2021 was ¥176,723,237.79, a decrease of 34.82% compared to ¥271,123,164.82 in 2020[32]. - The net profit after deducting non-recurring gains and losses was ¥53,309,874.16, down 70.34% from ¥179,764,504.15 in the previous year[32]. - The net cash flow from operating activities was ¥475,720,066.83, a decline of 13.09% from ¥547,361,013.97 in 2020[32]. - The total assets at the end of 2021 were ¥13,322,236,426.35, an increase of 8.14% from ¥12,319,715,091.57 at the end of 2020[32]. - The net assets attributable to shareholders at the end of 2021 were ¥6,102,062,628.27, up 2.21% from ¥5,969,876,957.74 in 2020[32]. - The company reported a basic earnings per share of ¥0.1869 for 2021, down 34.83% from ¥0.2868 in 2020[32]. - The weighted average return on equity for 2021 was 2.93%, a decrease of 1.69 percentage points from 4.62% in 2020[32]. - The company received government subsidies amounting to ¥142,156,783.61 in 2021, compared to ¥61,375,741.50 in 2020[34]. Business Expansion and Strategy - The company has expanded its main business to include electronic accelerator manufacturing, irradiation processing services, new materials, ecological environment, and medical health since the major asset restructuring completed in early 2017[25]. - The company aims to create a safer living environment and provide healthier life services through its nuclear technology initiatives[3][4][5]. - The company is actively expanding its business layout, including projects in special waste treatment and medical health, to create new competitive advantages[96]. - The company is enhancing its electronic accelerator technology to improve waste treatment capabilities and expand into new application areas[59]. - The company is focusing on the medical health sector, particularly in proton therapy equipment and medical isotopes, while also addressing market expansion challenges in these areas[152]. - The company is expanding its irradiation processing business, particularly in material modification, to meet the growing demand driven by new infrastructure projects in China[55]. Market Trends and Opportunities - The global irradiation processing industry is growing at an annual rate of approximately 10%, with China's industrial electron irradiation accelerators averaging over 10% growth in the past five years, and an expected growth rate of 10% to 15% from 2021 to 2025[36]. - The domestic medical sterilization service market currently holds a 12% industry share, indicating significant future growth potential[37]. - The market for electron beam treatment of special waste is expanding rapidly, particularly in industrial wastewater treatment, with notable achievements in sectors such as textile dyeing and medical waste[37]. - The domestic market for radioactive isotopes is heavily reliant on imports, with only 20% of the demand for 131I being met by domestic production, highlighting a significant opportunity for local production growth[41]. - The modified plastics industry has achieved significant advancements over the past decade, becoming a vital part of China's economy and narrowing the gap with developed countries[39]. Research and Development - The company holds 284 authorized patents, including 76 invention patents, demonstrating its strong R&D capabilities[80]. - Research and development expenses increased by 6.81% to ¥238,295,491.44 compared to the previous year[118]. - The number of R&D personnel rose by 18.05% to 556, with the proportion of R&D personnel in the company increasing to 12.16%[122]. - Total R&D investment amounted to ¥318,615,066.97, reflecting a 20.79% increase year-on-year[122]. - The company has established partnerships with three leading universities to foster innovation in nuclear technology[169]. Corporate Governance and Management - The company is committed to maintaining a "strict, cautious, detailed, and practical" work attitude in response to new challenges and tasks in the current environment[65]. - The company has established a robust internal control system and governance structure, ensuring compliance with legal and regulatory requirements[158]. - The company has established an independent asset structure with complete control over its production system and procurement processes[159]. - The company maintains a fully independent financial management system, with no instances of fund occupation by the controlling shareholder[163]. - The company emphasizes investor relations management to protect the rights of minority shareholders[159]. Future Outlook - The company expects a revenue growth of 10% for the upcoming fiscal year, projecting a total revenue of 11 billion RMB[172]. - The company plans to enhance ship safety management and increase operational efficiency in 2022, aiming for higher rental income through various pricing strategies[76]. - The company aims to strengthen accelerator research and manufacturing, focusing on applications in waste treatment, new materials, and health services[145]. - The 2022 operational plan emphasizes high-quality development and the implementation of the A+ strategy, positioning the year as a "year of implementation"[146]. - The company is exploring opportunities for mergers and acquisitions to strengthen its market position and expand its service offerings[185].